title: [T1G3 of the bladder: our experience].
abstract: From June 1991 to June 1995 we treated 20 patients affected by T1 G3 TCC of the bladder, 18 men and 2 women, with a mean age of 65.1 years (46-71). In 11 patients the disease was monofocal, with diameter of the tumor under 3.5 cms; in 5 patients monofocal with diameter of the tumor over 3.5 cms; in 1 patient multifocal and in 3 patients complex (mono or multifocal associated with CIS). The 11 patients with monofocal disease under 3.5 cms were treated with TUR-B, the other 9 (all males) were submitted to radical cystectomy with OINB diversion as first choice treatment. The mean follow up (all patients) was 3.2 years (6 months-14 years). Out of the patients of the former group only 3 did not show any relapse, the other 8 showed multiple relapses or metachronous tumors: 5 were treated with TUR-B+BCG, 3 were cystectomized. The patients submitted to cystectomy as first choice treatment did not show any progression of the disease after a mean follow-up of 19.8 months.
authors.affiliation: U.O. di Urologia, Busto Arsizio.
authors.forename: S
authors.initials: S
authors.lastname: Chisena
authors.forename: D
authors.initials: D
authors.lastname: Antonelli
authors.forename: S
authors.initials: S
authors.lastname: Bernasconi
authors.forename: A
authors.initials: A
authors.lastname: Zaroli
authors.forename: C
authors.initials: C
authors.lastname: Buizza
authors.forename: M
authors.initials: M
authors.lastname: Belloni
authors.forename: A
authors.initials: A
authors.lastname: Mandressi
mesh_terms: D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D003131:Combined Modality Therapy; D015653:Cystectomy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy
chemical_list: D001500:BCG Vaccine
vernacular_title: T1G3 della vescica: la nostra esperienza.